Innovent Biologics, Inc. reported revenue results for the first quarter of 2024. for the quarter, the Company achieved a total product revenue exceeding RMB 1.7 billion, representing a robust year-over-year growth of over 60%.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
38.35 HKD | +0.39% | -3.64% | -10.29% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.29% | 7.96B | |
-2.71% | 89.49B | |
+2.50% | 40.67B | |
-12.01% | 33.15B | |
+62.74% | 26.45B | |
-19.79% | 14.69B | |
-8.58% | 12.89B | |
-12.34% | 11.54B | |
-43.92% | 11.34B | |
+4.27% | 8.84B |
- Stock Market
- Equities
- 1801 Stock
- News Innovent Biologics, Inc.
- Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024